Navigation Links
Increase in drug development for killer diseases is not enough

A recent report shows that drug development for killer diseases such as HIV/AIDS, TB, Malaria, Chagas and Sleeping Sickness has increased in recent years. This is despite the fact that these diseases mainly affect the poor in developing countries and development of treatments is inhibitive due to lack of economic demand. Researchers argue that the rate of development of drugs (and of some vaccines and diagnostics) would increase if more incentives were created using patent rights and providing guarantees to purchase drugs for the poor as they are developed.

The report (The New Landscape of Neglected Disease Drug Development) by Mary Moran and colleagues at the Pharmaceutical Research and Development Policy Group, The George Institute, argues that drugs for neglected diseases are increasingly being developed partly due to the use of public-private partnership (PPPs) mechanisms that spread the financial and organisational risk of product development. Anne-Laure Ropars, from the George Institute will be discussing the rise of drug development for neglected diseases and the role of PPPs at a major international conference, organised by the ESRC Innogen Centre to be held in London on 5-6 September 2006.

Steven Matlin, Executive Director of the Global Forum for Health Research, also speaking at the conference, does not believe that the increases in development of health products for neglected diseases (drugs, vaccines and diagnostics) is simply due to the rise of PPPs. Matlin also stresses the rise of a group of 'innovating developing countries' (IDCs) including Brazil, China, India and South Africa. He argues that these countries have "growing national capacity for high-quality manufacturing to convert the inventions into health products for both domestic and international markets."

Matlin does acknowledge the challenges faced by both PPPs and IDCs in developing health products for neglected diseases. The third speaker in this conference sessi on, Robert Eiss, Executive Director of the Centre for the Management of Intellectual Property in Health Research, tackles these challenges in more depth. Eiss believes that correct market incentives and, in particular, appropriate intellectual property management are lacking. Eiss states that there is a "need to develop and promote forms of intellectual property management and technology transfer practice that help ensure access for the poor through the strategic use of such tools as price tiering and market segmentation, and the engagement of R&D and manufacturing capacities in countries where the targeted disease is endemic."


Source:Economic & Social Research Council

Related biology news :

1. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
2. Increased risk of osteoporosis associated with gene that one in five people have
3. WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas
4. Morphine for Chest Pain Increases Death Risk
5. Sea Ice May Be on Increase in the Antarctic
6. Use of Antibiotics for Acne May Increase Risk of Common Illness
7. Increased sensitivity to nerve signals keeps diabetes at bay
8. Increase in carbon dioxide emissions accelerating
9. A much-needed shot in the arm for HIV vaccine development
10. Clam embryo study shows pollutant mixture adversely affects nerve cell development
11. Zebrafish may hold key to understanding human nerve cell development
Post Your Comments:

(Date:11/17/2015)... Paris , qui ... Paris , qui s,est tenu du ... leader de l,innovation biométrique, a inventé le premier scanner ... sur la même surface de balayage. Jusqu,ici, deux scanners ... les empreintes digitales. Désormais, un seul scanner est en ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman ... AngelList early in their initial angel funding process. Now, they are paying it ... to make early stage investments in the microbiome space. In this, they ...
Breaking Biology Technology: